Zobrazeno 1 - 10
of 108
pro vyhledávání: '"I. Venturo"'
Autor:
I. Venturo, A. W. Tong, A. Mosiello, F. Alvino, C. Greco, F. Ameglio, M. Giampaolo, Cianciulli Am, G. Monte, G. M. Gandolfo
Publikováno v:
Cell Proliferation. 32:231-238
As at present only a long‐term follow‐up can fully determine whether monoclonal gammapathies of undetermined significance (MGUS) will evolve into multiple myeloma (MM), this study attempted to identify other variables connected with the amount of
Autor:
Paola Nisticò, PG De Berardinis, C. Buono, T Alonzi, I Venturo, P. G. Natali, Stefania Morrone
Publikováno v:
Journal of Clinical Investigation. 94:1426-1431
Cell-mediated immune response to breast tumor has only been marginally investigated. To gain insight into this issue we have developed two clones of distinct phenotype, CD3+ alpha/beta, CD4+, CD8-, CD16-, and CD3+ alpha/beta, CD4-, CD8+, CD16-, respe
Publikováno v:
Journal of experimentalclinical cancer research : CR. 22(4)
We measured the serum levels of p53 mutant protein (p53M-ELISA) in 65 patients with plasma cell dyscrasia (PCD) and compared them with some conventional laboratory variables. Our aim was to assess, for the first time, the potential of this parameter
Autor:
F, Guadagni, P, Ferroni, S, Carlini, S, Mariotti, A, Spila, S, Aloe, R, D'Alessandro, M D, Carone, A, Cicchetti, A, Ricciotti, I, Venturo, P, Perri, F, Di Filippo, F, Cognetti, C, Botti, M, Roselli
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
Carcinoembryonic antigen (CEA) is still a widely used test for monitoring breast cancer, although recent reports discourage its routine use because of low sensitivity. This is a prospective study evaluating the efficacy of CEA and CA 15.3 in monitori
Autor:
S, Alvino, M, Marcucci, D, Canzoniere, A, Mosiello, G, Del Monte, I, Venturo, M, Rinaldi, G M, Gandolfo, M, Lopez, C, Greco
Publikováno v:
La Clinica terapeutica. 150(3)
To determine the role of serum levels of IL-6 and p53 mutant protein as well as of c-myc proto-oncogene alterations: a) in discriminating between benign (MGUS) and malignant Plasma cell dyscrasias (Multiple and Microsecreting Myeloma, Plasmocytoma);
Autor:
G, Paoletti, L, Di Lauro, T, Gionfra, I, Venturo, F, Belli, E, Squilloni, S, Mariotti, G, Fioretti, M, Gemini, R, Tersigni, M, Lopez
Publikováno v:
La Clinica terapeutica. 149(2)
To evaluate the efficacy and toxicity of a sequential low-dose methotrexate (MTX) and 5-fluorouracil (5FU) regimen in the palliative treatment of patients with advanced colorectal cancer.Enrolled in the study were patients with advanced colorectal ca
Autor:
A M, Cianciulli, A M, Coletta, B, Pescatore, C, Greco, G, Del Monte, C, Leonardo, I, Venturo, G M, Gandolfo
Publikováno v:
European journal of histochemistry : EJH. 41
Publikováno v:
Anticancer research. 16(5A)
In recent years, significant progress has been made in identifying characteristic chromosomal and molecular rearrangements associated with several solid tumors. Most solid tumors studied have been found to be characterized by recurrent chromosomal ab
Publikováno v:
The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). 39(4 Suppl 1)
Somatostatin receptors have been identified on the cellular surface of a subset of patients with small cell lung cancer (SCLC) and may be associated with a less aggressive evolution of the tumor. Moreover, medical therapy with somatostatin analogues